v3.26.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net sales $ 651,000 $ 651,600 $ 1,243,100 $ 1,237,000
Cost of goods sold 305,200 306,300 587,900 585,700
Gross profit 345,800 345,300 655,200 651,300
Selling, general and administrative expense 212,000 207,700 424,400 416,500
Research and Development Expense 61,200 60,500 124,100 134,000
Segment profit (loss) 72,600 77,100 106,700 100,800
Interest expense 12,100 12,600 24,400 24,600
Foreign exchange (gains) losses, net (200) 1,100 (2,600) (1,600)
Marketable Securities, Unrealized (Gain) Loss (458,000) (334,400) 280,200 (366,200)
Other Nonoperating Income (Expense) 23,400 16,200 47,600 53,400
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 542,100 414,000 (147,700) 497,400
(Provision) benefit for income taxes (170,700) (96,200) (8,000) (115,600)
Net income attributable to Bio-Rad $ 371,400 $ 317,800 $ (155,700) $ 381,800
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 13.89 $ 11.67 $ (5.80) $ 13.84
Weighted average common shares - basic 26,746 27,226 26,852 27,581
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 13.85 $ 11.67 $ (5.80) $ 13.84
Weighted average common shares - diluted 26,814 27,228 26,852 27,589